Abstract: A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V? variable domain of the light chain.

Abstract: The invention concerns the expression in a baculovirus-insect cell system of receptors with seven transmembrane domains, in particular receptors coupled to proteins (;, in particular olfactory receptors, under the transcriptional control of a promoter derived from the polyhedrin promoter by deletion of all or part of the region of said promoter extending from ?1 to ?12 positions relative to the initiation site of the polyhedrin translation.

Abstract: A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V? variable domain of the light chain.

Abstract: Recombinant baculovirus used as an expression vector in the production of immunoglobulins with an insect cell. The invention is characterized by a first expression cassette comprising a first sequence coding for at least one portion of an immunoglobulin heavy chain, wherein the sequence is transcriptionally controlled by a first baculovirus promoter, and a second expression cassette comprising a second sequence coding for at least one portion of an immunoglobulin light chain, said second sequence being transcriptionally controlled by a second baculovirus promoter. The first and second promoters are two different promoters or derivatives of different promoters, the first and second promoters residing at different loci.

Abstract: An isolated CDR-derived polypeptide from monoclonal antibody 13B8.2, a pharmaceutical composition including a pharmaceutically acceptable carrier and at least a peptide, and a method for treating a subject suffering from an autoimmune disorder, including administering to the subject a therapeutically effective amount of a pharmaceutical composition, a method for treating a subject suffering from a transplant rejection including administering to the subject a therapeutically effective amount of a pharmaceutical composition, a method for treating a subject suffering from an HIV immunodeficiency disorder including administering to the subject a therapeutically effective amount of a pharmaceutical composition and a method for treating a subject suffering from a tumoral disorder including administering to the subject a therapeutically effective amount of a pharmaceutical composition.

Abstract: A recombinant vector useful for regulating the expression of a gene contred by a baculovirus polyhedrin promoter or P10 promoter, via a sequence forming an RAR-type hormone receptor binding site.

Abstract: The present invention describes modified baculoviruses possessing unique restriction endonuclease cleavage sites downstream of the promoter of the baculovirus viral inclusion, polyhedron and/or protein P10 genes and a method for obtaining such modified baculoviruses. Such modified baculoviruses are useful for the direct cloning of heterologous DNA into the unique endonuclease restriction sites and the consequent expression of the heterologous DNA inserted therein.

Abstract: A DNA sequence derived by the mutation from a ColE1-type replication origin is provided, wherein the sequence is characterized in that it includes at least one of the following mutations, which are defined in relation to the wild ColE1 origin: a Guanine to Adenine transversion in position 2976; and a Guanine deletion in position 3057. This sequence increases the number of copies of the plasmids which include it. Plasmids containing the replication origin, and their uses in the amplification of DNA sequences and the production of polypeptides by genetic engineering, are also disclosed.